ISENTRESS 100 mg (raltegravir), granules for oral suspension, antiretroviral

VIROLOGY - New form

Opinions on drugs - Posted on Apr 14 2016

Inclusion

ISENTRESS 100 mg, granules for oral suspension, has Marketing Authorisation, in combination with other antiretroviral medicinal products, in the treatment of infection with the human immunodeficiency virus (HIV-1) in adults, adolescents, children, young children and infants over 4 weeks old and weighing between 3 and < 20 kg.
It is a treatment option, only for children at a therapeutic impasse and in the absence of viral mutations reducing the sensitivity to this substance and to the at least two other ARVs that will be used in combination.
On account of the high risk of resistant mutations emerging in cases of virological failure, it is essential to use raltegravir with at least 2 active antiretroviral agents.